Excitotoxicity of quinolinic acid: modulation by endogenous antagonists.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical and biochemical mechanisms without human data
PubMed 16787837 · doi:10.1007/BF03033790
What was done
This narrative review synthesized preclinical and biochemical evidence on quinolinic acid (QUIN) excitotoxicity mediated by NMDA receptors. It examined differential neuronal subtype susceptibility, modulation by endogenous tryptophan metabolites (such as kynurenic acid and picolinic acid), manipulation of kynurenine pathway enzymes, and the modulating role of nitric oxide.
What was found
The abstract reports no numerical data or effect sizes. It reports that QUIN depletes biochemical markers for dopaminergic, cholinergic, GABAergic, enkephalinergic, and NADPH diaphorase neurons. Kynurenic acid blocks NMDA and non-NMDA receptor activity, and inhibiting kynurenine hydroxylase and kynureinase elevates brain kynurenic acid to protect against QUIN toxicity. Picolinic acid, quinaldic acid, hydroxyquinaldic acid, and nitric oxide donors also reduce excitotoxicity across preclinical models.
Why it matters
Identifying endogenous antagonists and regulatory enzymes within the kynurenine pathway provides actionable mechanistic targets for designing neuroprotective therapies against NMDA-mediated neurodegenerative injury.
Limits
The review relies entirely on preclinical and biochemical models, with no clinical human data or quantitative effect sizes reported in the abstract. The actual presence and physiological concentrations of several discussed protective metabolites (such as quinaldic and picolinic acid) in the brain remain unconfirmed.
Cited by
- supports Kynurenic acid acts as an NMDA receptor antagonist, whereas quinolinic acid acts as an NMDA receptor agonist with neurotoxic properties.